Date: February 18, 2011
URL: http://www.google.com/patents/about?id=mAToAQAAEBAJ
B-cell depleting agents for the treatment of chronic fatigue syndrome
---------------------------------------------------------------------
Abstract
The present invention relates in a first aspect to a B-cell depleting
anti-CD20 antibody or a CD20-binding antibody fragment thereof for the
treatment of chronic fatigue syndrome and myalgic encephalomyelitis.
In particular, the present invention relates to the use of anti-CD20
monoclonal antibodies or fragments thereof which are preferably
humanized for the treatment of chronic fatigue syndrome/myalgic
encephalomyelitis in a subject afflicted with said disease.
Inventors
Olav Mella, Oystein Fluge
Current U.S. Classification
424/134.1; 424/130.1; 424/133.1; 424/142.1; 514/44/R; 514/249
Claims
What is claimed is:
1. A method of treating chronic fatigue syndrome and, optionally,
myalgic encephalomyelitis comprising the step of administering a
B-cell depleting agent to a subject afflicted therewith, whereby said
B-cell depleting agent is not a B-cell depleting CD-20 antibody or
CD-20-binding antibody fragment thereof.
2. The method of treating chronic fatigue syndrome and, optionally,
myalgic encephalomyelitis according to claim 1 comprising the step of
administering a B-cell depleting agent to a subject afflicted
therewith, whereby said B-cell depleting agent is selected from a
BLyS-specific inhibitor, an anti-BAFF antibody or anti-BAFF binding
antibody fragment thereof, an anti-CD22 antibody or anti-CD22 binding
antibody fragment thereof.
3. The method for treating chronic fatigue syndrome and, optionally,
myalgic encephalomyelitis as recited in claim 1 wherein said step of
administering includes providing said B-cell depleting agent to said
subject afflicted therewith one or two infusions twice within two weeks.
4. The method of treating chronic fatigue syndrome and, optionally,
myalgic encephalomyelitis according to claim 1 wherein Methotrexate
and/or a B-cell depleting anti-CD20 antibody or CD20 binding antibody
fragment thereof is administered simultaneously, separately or
sequentially with said B-cell depleting agent as identified in claim 1
to said subject.
5. The method of treating chronic fatigue syndrome and, optionally,
myalgic encephalomyelitis according to claim 1, wherein said B-cell
depleting agent is an anti-BLyS antibody or BLyS-binding antibody
fragment thereof.
6. The method of treating chronic fatigue syndrome and, optionally,
myalgic encephalomyelitis according to claim 5, wherein said anti-BLyS
antibody is Belimumab.
7. The method of treating chronic fatigue syndrome and, optionally,
myalgic encephalomyelitis according to claim 1, wherein said B-cell
depleting agent is selected from group consisting of Belimumab,
Atacicept. Briobacept, Epretuzumab, Abatacept, Abetimus.
8. The method of treating chronic fatigue syndrome and, optionally,
myalgic encephalomyelitis according to claim 1, wherein said B-cell
depleting agent is a monoclonal antibody or antibody fragment thereof.
9. The method of treating chronic fatigue syndrome and, optionally,
myalgic encephalomyelitis according to claim 8, wherein said B-cell
depleting antibody is a humanized antibody or antibody fragment thereof.
10. The method of treating chronic fatigue syndrome and, optionally,
myalgic encephalomyelitis according to claim 1 wherein said B-cell
depleting agent is an antibody fragment selected from the group
consisting of F (ab?)2, F(ab?), Fab, Fv and sFv.
11. The method of treating chronic fatigue syndrome and, optionally,
myalgic encephalomyelitis according to claim 1, wherein said B-cell
depleting agent is administered in an amount in the rage on 10 mg to
5000 mg per dosage.
12. The method of treating chronic fatigue syndrome and, optionally,
myalgic encephalomyelitis according to claim 1, wherein said B-cell
depleting agent is administered to said subject in a single
therapeutically effective dosage of said agent of 50 to 2000 mg/m2 or
multiple of therapeutically effective dosage of said agent of 50 to
2000 mg/m2.
--------
(c) 2011 Google
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
Co-Cure Archives: http://listserv.nodak.edu/archives/co-cure.html
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
